Source of Support: None, Conflict of Interest: None
Three groups of patients with chronic obstructive pulmonary disease (COPD) of comparable age and sex were administered either deriphylline or salbutamol or terbutaline orally for three weeks. Peak expiratory flow rate (PEFR) of each patient was estimated before and at the end of three weeks of therapy. There was significant rise in PEFR values in the two groups of patients who received either salbutamol or terbutaline whereas in case of patients who received deriphylline there was no significant change. The results of the study suggest that there is need to assess the efficacy of bronchodilator therapy and especially that of deriphylline objectively for determining optimal maintenance therapy of COPD.